Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipafricept with Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
NCT02050178Phase 1Completed
- Sponsor
- OncoMed Pharmaceuticals
- Start
- Nov 2013
- Primary completion
- Jun 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipafricept in pancreatic ductal adenocarcinoma (PDAC), sponsored by OncoMed Pharmaceuticals. Primary endpoint: Safety and tolerability of OMP-54F28 in combination with nab-paclitaxel and gemcitabine. Started Nov 2013; status: completed.
02
Drugs
ipafricept
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02050178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02050178.